Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
BackgroundZurawski, V. R., Orjaseter, H., Andersen, A., & Jellum, E. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420507 · Cited by 268
Takano, M., Kikuchi, Y., Yaegashi, N., Kuzuya, K., Ueki, M., Tsuda, H., Suzuki, M., Kigawa, J., Takeuchi, S., Tsuda, H., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603116 · Cited by 266 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundProspective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer
Menon, U., Skates, S. J., Lewis, S., Rosenthal, A. N., Rufford, B., Sibley, K., MacDonald, N., Dawnay, A., Jeyarajah, A., Bast, R. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6642 · Cited by 243 · cited 1×
“A related observation is that serum CA125 levels are elevated in 80% of patients with advanced stage epithelial ovarian carcinoma but are increased in only 60% of patients with early stage disease [27,28].”
BackgroundGilks, C. B., Ionescu, D. N., Kalloger, S. E., Köbel, M., Irving, J., Clarke, B., Santos, J., Le, N., Moravan, V., & Swenerton, K. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.01.003 · Cited by 242 · cited 1×
“]. These subtypes differ dramatically in frequency, when early stage carcinomas (where the majority are nonserous carcinomas [”
BackgroundSelf-citationImmunohistochemical Detection of the Wilms' Tumor Gene (WT1) in Epithelial Ovarian Tumors
Shimizu, M., Toki, T., Takagi, Y., Konishi, I., & Fujii, S. (2000) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200004000-00010 · Cited by 187 · cited 1×
“WT1 is a widely used diagnostic marker for the serous subtype [30] and is an example for how analysis of the entire cohort can give misleading results.”
BackgroundBertheau, P., Turpin, E., Rickman, D. S., Espié, M., de Reyniès, A., Feugeas, J.-P., Plassa, L.-F., Soliman, H., Varna, M., de Roquancourt, A., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040090 · Cited by 173 · cited 1×
“Cancer treatment in general is beginning to move towards therapies tailored for specific cancer subtypes (e.g., breast carcinoma and lymphoma [ 24 ,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundExpression of progesterone receptor is a favorable prognostic marker in ovarian cancer
Lee, P., Rosen, D. G., Zhu, C., Silva, E. G., & Liu, J. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.11.010 · Cited by 160 · cited 1×
“Marker Selection and Immunohistochemistry The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [14–19] or being developed as early detection markers in ovarian carcinomas [20].”
MethodGilks, C. B. (2004) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000130446.84670.93 · Cited by 116 · cited 1×
“These subtypes differ dramatically in frequency, when early stage carcinomas (where the majority are nonserous carcinomas [5]) and advanced stage carcinomas (which are predominantly of serous subtype [6]) are compared.”
BackgroundSelf-citationDuncan, T. J., Al‐Attar, A., Rolland, P., Scott, I., Deen, S., Liu, D. T. Y., Spendlove, I., & Durrant, L. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1888 · Cited by 110 · cited 1×
“We hope these data will end the lumping of ovarian carcinoma subtypes within biomarker studies, as is the current practice [38–41].”
ResultHOXA11 DNA methylation—A novel prognostic biomarker in ovarian cancer
Fiegl, H., Windbichler, G. H., Mueller‐Holzner, E., Goebel, G., Lechner, M., Jacobs, I. J., & Widschwendter, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23563 · Cited by 104
Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian Cancer
Palmer, C., Duan, X., Hawley, S. J., Scholler, N., Thorpe, J. D., Sahota, R. A., Wong, M. Q., Wray, A., Bergan, L. A., Drescher, C. W., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002633 · Cited by 88 · cited 1×
“Marker Selection and Immunohistochemistry The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [14–19] or being developed as early detection markers in ovarian carcinomas [20].”
MethodSelf-citationNarod, S. A., & Boyd, J. A. (2002) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200202000-00004 · Cited by 87 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
BackgroundPrentice, L., Klausen, C., Kalloger, S. E., Köbel, M., McKinney, S. E., Santos, J. L., Kenney, C., Mehl, E., Gilks, C. B., Leung, P. C. K., et al. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-33 · Cited by 73 · cited 4×
“Four other biomarkers (KISS1, K-Cadherin, Mesothelin, Ki-67) that were significant in the entire cohort did not show significance in any subtype.”
MethodInfluentialSelf-citationAnttila, M., Kosma, V., Ji, H., Wei-Ling, X., Puolakka, J. O., Juhola, M., Saarikoski, S., & Syrjänen, K. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2591 · Cited by 70 · cited 1×
“Another example is Ki-67; there are conflicting results on the prognostic value of Ki-67 in ovarian carcinoma [31–36].”
ResultBauer, C., Diesinger, I., Brass, N., Steinhart, H., Iro, H., & Meese, E. U. (2001) · Cancer · doi:10.1002/1097-0142(20010815)92:4<781::aid-cncr1383>3.0.co;2-p · Cited by 70
Lassus, H., Leminen, A., Lundin, J., Lehtovirta, P., & Butzow, R. (2003) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.08.034 · Cited by 68 · cited 1×
“Except KISS1 [21] and p53 [22] where recently published cut-off points were used, all markers were dichotomized into negative and positive cases (cut-off values for positive versus negative for all markers except Ki-67 are shown in Table S1).”
MethodBoth Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival
Bartel, F., Jung, J., Böhnke, A., Gradhand, E., Zeng, K., Thomssen, C., & Hauptmann, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1192 · Cited by 67 · cited 1×
“We hope these data will end the lumping of ovarian carcinoma subtypes within biomarker studies, as is the current practice [38–41].”
ResultMoreno, C. S., Matyunina, L. V., Dickerson, E. B., Schubert, N., Bowen, N. J., Logani, S., Benigno, B. B., & McDonald, J. F. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000441 · Cited by 65 · cited 1×
“Marker Selection and Immunohistochemistry The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [14–19] or being developed as early detection markers in ovarian carcinomas [20].”
MethodSelf-citationYamamoto, S., Tsuda, H., Yoshikawa, T., Kudoh, K., Kita, T., Furuya, K., Tamai, S., & Matsubara, O. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000249449.13466.3c · Cited by 63 · cited 1×
“Another example is Ki-67; there are conflicting results on the prognostic value of Ki-67 in ovarian carcinoma [31–36].”
ResultKorkolopoulou, P. A., Vassilopoulos, I., Konstantinidou, A. E., Zorzos, H., Patsouris, E., Agapitos, E. B., & Davaris, P. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6627 · Cited by 60 · cited 1×
“Another example is Ki-67; there are conflicting results on the prognostic value of Ki-67 in ovarian carcinoma [31–36].”
ResultKhouja, M. H., Baekelandt, M. M. O., Nesland, J. M., & Holm, R. (2007) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31804216a0 · Cited by 52 · cited 1×
“Another example is Ki-67; there are conflicting results on the prognostic value of Ki-67 in ovarian carcinoma [31–36].”
ResultSillanpää, S. M., Anttila, M., Voutilainen, K., Ropponen, K. M., Sironen, R. K., Saarikoski, S. V., & Kosma, V. (2006) · International Journal of Cancer · doi:10.1002/ijc.22067 · Cited by 39 · cited 1×
“, we confirmed that MMP7 expression is a strong independent prognostic factor for favourable prognosis in the entire cohort, as shown previously [29] as well as for highgrade serous and endometrioid subtypes.”
BackgroundViale, G., Maisonneuve, P., Bonoldi, E., Bacco, A. D., Bevilacqua, P., Panizzoni, G. A., Radaelli, U., & Gasparini, G. (1997) · Annals of Oncology · doi:10.1023/a:1008253429700 · Cited by 39 · cited 1×
“Marker Selection and Immunohistochemistry The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [14–19] or being developed as early detection markers in ovarian carcinomas [20].”
MethodMünstedt, K., von Georgi, R., & Franke, F. E. (2004) · Cancer Investigation · doi:10.1081/cnv-120030206 · Cited by 27 · cited 1×
“Another example is Ki-67; there are conflicting results on the prognostic value of Ki-67 in ovarian carcinoma [31–36].”
ResultSummary and discussion of session recommendations
Trimble, E. L., Fountain, J. W., & Birrer, M. J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.08.022 · Cited by 26 · cited 1×
“]. Therefore, the National Cancer Institute (NCI) State of Science meeting recently singled out clear cell carcinoma as a candidate for clinical trials to identify more active therapy than what is currently available [”
BackgroundHøgdall, E. V. S., Christensen, L. H., Kjær, S. K., Blaakær, J., Christensen, I. J., Gayther, S. A., Jacobs, I. J., & Høgdall, C. K. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.03.043 · Cited by 26 · cited 1×
“This inverse association in a subgroup, also known as Simpson’s paradox, will not typically be revealed by multivariable analysis [ 19 ].”
BackgroundGreen, J. A., Berns, E., Coens, C., van Luijk, I. F., Thompson-Hehir, J., van Diest, P. J., Verheijen, R. H. M., van de Vijver, M. J., van Dam, P., Kenter, G. G., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.015 · Cited by 25 · cited 1×
“Another example is Ki-67; there are conflicting results on the prognostic value of Ki-67 in ovarian carcinoma [31–36].”
ResultPrognostic role of topoisomerase-IIα in advanced ovarian cancer patients
Ferrandina, G., Petrillo, M., Carbone, A., Zannoni, G., Martinelli, E. M., Prisco, M. G., Pignata, S., Breda, E., Savarese, A., & Scambia, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604410 · Cited by 23
Prognostic indices in ovarian cancer: Their significance in treatment planning
Swenerton, K. D. (1992) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.1992.tb00009.x · Cited by 10
Self-citationParwani, A. V. (2009) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/s1077-9108(08)79154-0 · Cited by 2
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
International Statistical Classification of Diseases and Related Health Problems
Eisfeld, J. (2014) · TSQ: Transgender Studies Quarterly · doi:10.1215/23289252-2399740 · Cited by 3,570
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Self-citationRethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.